Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

Inflammatory markers as selection criteria of hepatocellular carcinoma in living-donor liver transplantation.

Na GH, Kim DG, Han JH, Kim EY, Lee SH, Hong TH, You YK.

World J Gastroenterol. 2014 Jun 7;20(21):6594-601. doi: 10.3748/wjg.v20.i21.6594.

2.

Clinical outcome in patients with hepatocellular carcinoma after living-donor liver transplantation.

Choi HJ, Kim DG, Na GH, Han JH, Hong TH, You YK.

World J Gastroenterol. 2013 Aug 7;19(29):4737-44. doi: 10.3748/wjg.v19.i29.4737.

3.

Prognostic factors affecting survival at recurrence of hepatocellular carcinoma after living-donor liver transplantation: with special reference to neutrophil/lymphocyte ratio.

Harimoto N, Shirabe K, Nakagawara H, Toshima T, Yamashita Y, Ikegami T, Yoshizumi T, Soejima Y, Ikeda T, Maehara Y.

Transplantation. 2013 Dec 15;96(11):1008-12. doi: 10.1097/TP.0b013e3182a53f2b.

PMID:
24113512
4.

Serum C-reactive protein is a useful biomarker for predicting outcomes after liver transplantation in patients with hepatocellular carcinoma.

An HJ, Jang JW, Bae SH, Choi JY, Yoon SK, Lee MA, You YK, Kim DG, Jung ES.

Liver Transpl. 2012 Dec;18(12):1406-14. doi: 10.1002/lt.23512.

5.

Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment.

Motomura T, Shirabe K, Mano Y, Muto J, Toshima T, Umemoto Y, Fukuhara T, Uchiyama H, Ikegami T, Yoshizumi T, Soejima Y, Maehara Y.

J Hepatol. 2013 Jan;58(1):58-64. doi: 10.1016/j.jhep.2012.08.017. Epub 2012 Aug 25.

PMID:
22925812
6.

Section 5. Further expanding the criteria for HCC in living donor liver transplantation: when not to transplant: SNUH experience.

Lee KW, Yi NJ, Suh KS.

Transplantation. 2014 Apr 27;97 Suppl 8:S20-3. doi: 10.1097/01.tp.0000446269.20934.d3.

PMID:
24849825
7.

Living donor liver transplantation for hepatocellular carcinoma.

Isik B, Ince V, Karabulut K, Kayaalp C, Yilmaz S.

Transplant Proc. 2012 Jul-Aug;44(6):1713-6. doi: 10.1016/j.transproceed.2012.05.033.

PMID:
22841251
8.

Living Donor Liver Transplantation for Hepatocellular Carcinoma within Milan Criteria in the Present Era.

Yoshizumi T, Harimoto N, Itoh S, Okabe H, Kimura K, Uchiyama H, Ikegami T, Ikeda T, Maehara Y.

Anticancer Res. 2016 Jan;36(1):439-45.

PMID:
26722079
9.

Evaluation methods for pretransplant oncologic markers and their prognostic impacts in patient undergoing living donor liver transplantation for hepatocellular carcinoma.

Shindoh J, Sugawara Y, Nagata R, Kaneko J, Tamura S, Aoki T, Sakamoto Y, Hasegawa K, Tanaka T, Kokudo N.

Transpl Int. 2014 Apr;27(4):391-8. doi: 10.1111/tri.12274. Epub 2014 Feb 21.

10.

A scoring model based on neutrophil to lymphocyte ratio predicts recurrence of HBV-associated hepatocellular carcinoma after liver transplantation.

Wang GY, Yang Y, Li H, Zhang J, Jiang N, Li MR, Zhu HB, Zhang Q, Chen GH.

PLoS One. 2011;6(9):e25295. doi: 10.1371/journal.pone.0025295. Epub 2011 Sep 26.

11.

Living donor liver transplantation in hepatocellular carcinoma beyond the Milan criteria.

Woo HY, Jang JW, Choi JY, You CR, Jeong SW, Bae SH, Yoon SK, Lee YS, Kim DG.

Liver Int. 2008 Sep;28(8):1120-8. doi: 10.1111/j.1478-3231.2008.01785.x. Epub 2008 May 20.

PMID:
18492023
13.

Pretransplant serum levels of C-reactive protein predict prognoses in patients undergoing liver transplantation for hepatocellular carcinoma.

Kim YK, Kim SH, Lee SD, Hong SK, Park SJ.

Transplant Proc. 2015 Apr;47(3):686-93. doi: 10.1016/j.transproceed.2014.11.048.

PMID:
25891712
14.

Neutrophil-lymphocyte ratio predicts the prognosis of patients with hepatocellular carcinoma after liver transplantation.

Xiao GQ, Liu C, Liu DL, Yang JY, Yan LN.

World J Gastroenterol. 2013 Dec 7;19(45):8398-407. doi: 10.3748/wjg.v19.i45.8398.

15.

Living donor liver transplantation does not increase tumor recurrence of hepatocellular carcinoma compared to deceased donor transplantation.

Xiao GQ, Song JL, Shen S, Yang JY, Yan LN.

World J Gastroenterol. 2014 Aug 21;20(31):10953-9. doi: 10.3748/wjg.v20.i31.10953.

16.
17.

Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series.

Sugawara Y, Tamura S, Makuuchi M.

Dig Dis. 2007;25(4):310-2.

PMID:
17960065
18.
19.

Clinical Impact of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma.

Lee SD, Kim SH, Kim SK, Kim YK, Park SJ.

Transplantation. 2015 Oct;99(10):2142-9. doi: 10.1097/TP.0000000000000719.

PMID:
25905981
20.

Living-donor liver transplantation associated with higher incidence of hepatocellular carcinoma recurrence than deceased-donor liver transplantation.

Park MS, Lee KW, Suh SW, You T, Choi Y, Kim H, Hong G, Yi NJ, Kwon CH, Joh JW, Lee SK, Suh KS.

Transplantation. 2014 Jan 15;97(1):71-7. doi: 10.1097/TP.0b013e3182a68953.

PMID:
24056623

Supplemental Content

Support Center